The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1709
ISSUE 1709
August 19, 2024
Issue 1709
- Donanemab (Kisunla) for Alzheimer's Disease
- Ensifentrine (Ohtuvayre) for COPD
- Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
- Ryzneuta for Prevention of Febrile Neutropenia
- In Brief: Expanded Indication for Elevidys
- Adagrasib (Krazati) for Colorectal Cancer (online only)
- Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)
- In Brief: A New Torsemide Formulation (Soaanz) for Edema (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Donanemab (Kisunla) for Alzheimer's Disease
August 19, 2024 (Issue: 1709)
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed
monoclonal antibody, has been approved by
the FDA for treatment of Alzheimer's disease (AD).
The label states that the drug should only be started
in patients with mild cognitive...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.